complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.

Author: Sasho Dikus
Country: Uruguay
Language: English (Spanish)
Genre: Education
Published (Last): 2 January 2005
Pages: 112
PDF File Size: 12.68 Mb
ePub File Size: 6.44 Mb
ISBN: 977-4-36308-123-7
Downloads: 5487
Price: Free* [*Free Regsitration Required]
Uploader: Gardanris

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. These agents could enhance epirubicin’s activity. Semin Oncol ;24 5 Suppl Topical cooling does not reduce anthracycline skin concentrations but decreases cellular uptake of anthracyclines thereby decreasing the cytotoxic effect.

This simple act of changing the conformation of DNA can interfere with strand elongation roxorrubicina inhibiting DNA polymerase and can inhibit protein synthesis due to effects on RNA polymerase. Treatment required colony stimulating factor support.

Live virus vaccines are contraindicated during therapy with antineoplastic agents due to the potentiation of virus replication, adverse reactions to the virus, and the immunocompromised status of the patient. Administration of epirubicin destroys any GP activity present in cardiac cells. These reactions may lead to phlebitis. Two cases of acute lymphoid leukemia ALL have been reported in patients receiving epirubicin.

Several compounds including cyclosporine, cyclosporine analogs and verapamil may block this protein and reverse resistance. Epirubicin and other anthracyclines induce cytotoxicity through several different mechanisms.

There was a problem providing the content you requested

La epirubicina tiene un espectro similar de mecanismk y de toxicidad a los de la doxorrubicina. Epirubicin has a triphasic clearance with half-lives for the alpha, beta, and terminal phases of 3 minutes, 1 hour, and 30 hours, respectively. Epirubicin is a vesicant, and administration into soft tissue can cause pain, burning, tissue necrosis and skin ulcer.


Epirubicin-induced free radical formation contributes to its cardiotoxicity. Clinicians should consult the appropriate references to verify the dose.

Doxorruubicina prevent uric acid nephropathy in epirubicin-induced hyperuricemia, allopurinol is preferred over uricosuric agents. The dose of epirubicin should be adjusted for elevations in the total doxodrubicina or AST because these patients will have a decreased clearance of epirubicin with an increase in overall toxicity see Dosage. Cimetidine therapy should be stopped during epirubicin doxorruibcina. The coadministration of paclitaxel or docetaxel did not affect the pharmacokinetics of epirubicin when epirubicin was given immediately following the taxane.

Epirubicin is an anthracycline chemotherapy agent and is the 4′-epimer of doxorubicin and a semi-synthetic derivative of daunorubicin. Patients who have had previous radiation therapy may experience radiation recall reactions during epirubicin therapy. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone VECD as induction and salvage treatment in multiple myeloma. At equimolar doses, epirubicin is less myelotoxic than doxorubicin.

Medicamentos de quimioterapia

Doxorruhicina to aspirate the drug prior to removing the needle. Br J Cancer ; Most patients recover by the third week of therapy. Nail discoloration, photosensitivity, and skin discoloration have been reported. Epirubicin is a radiation sensitizer and should be used with caution in patients receiving concurrent radiation therapy; although in some cases this may be a benefit.

Medicamentos de quimioterapia

Use care to avoid accidental exposure to epirubicin during preparation, handling, and administration. Metabolism of epirubicin occurs through four major routes: Because antineoplastic agents exert their toxic effects against rapidly growing cells, such as hematopoietic progenitor cells, sargramostim, GM-CSF, and filgrastim, G-CSF, are contraindicated for use in patients within 24 hours of treatment with antineoplastic agents.


Epirubicin has also been studied in combination with vinorelbine and as a single-agent therapy. Patients should be closely monitored during IV infusions for signs and symptoms of extravasation such as poor blood return, burning, stinging, and swelling at the injection site.

As this can be a progressive injury, appropriate long-term follow-up is required.

Previous irradiation to the left chest is associated with an increased risk of developing CHF and an accelerated mortality. Dosage adjustments are required for patients with hepatic or renal dysfunction.

Patients with prior treatment with radiation therapy or anthracyclines may have decreased ability to tolerate trastuzumab therapy. If a woman becomes pregnant during therapy, she should be advised of the potential risks to the fetus.

This may manifest as reduced LVEF, tachycardia, dyspnea, pulmonary edema, hepatomegaly, ascites, pleural effusion, or gallop rhythm. Acute cardiotoxicity can occur during administration of epirubicin; a mexanismo, dose-dependent cardiomyopathy may also occur. Anaphylactoid reactions and urticaria may mecabismo following epirubicin administration. Dosage For the adjuvant treatment of breast cancer: Signs of myelosuppression include pancytopenia, leukopenia, neutropenia, thrombocytopenia, and anemia.